Skip to content
value.today

Elite Pharmaceuticals Inc /de/

Elite Pharmaceuticals Inc /de/ is listed today as Elite Pharmaceuticals, Inc.: market value, financials and filings are on its company page.

Funding rounds

0 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Elite Pharmaceuticals Inc /de/
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2009$1 MA long-registered or listed companyUnder $2 million

Elite Pharmaceuticals Inc /de/: Private sale, Jun 2009

Investors in this round

1 investor had bought by the notice of Jun 12, 2009: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $4 M offered; $3 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$122,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Chris Dick · Executive Officer, Director
  • Mark Gittelman · Executive Officer
  • Barry Dash · Director
  • Jerry Treppel · Director
  • Melvin Van Woert · Director
  • Robert J. Levenson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Amount represents payments to be made as salaries of executive officers and accrued directors' fees in the ordinary course of business.”

Signed by Chris Dick, Acting Chief Executive Officer. Source: SEC Form D, newest notice filed Jun 12, 2009. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Elite Pharmaceuticals, Inc., its revenue in fiscal 2026 came from these product and service lines: Manufacturing $147.81 million (99%), Manufacturing Fees $147.81 million (99%), Scheduled Products Manufacturing Fees $141.47 million (95%), Indirect Sales to Wholesalers $82.54 million (55%), Direct Sales to Wholesalers $65.27 million (44%).

    Annual report (SEC XBRL) · Mar 2026

  • Elite Pharmaceuticals Inc /de/ chose not to state its revenue in its newest notice of a funding round (Jun 2009).

    SEC Form D · Jun 2009

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jun 2009

Products and services#

No products or services of Elite Pharmaceuticals Inc /de/ are on record.

Investors#

No investor of Elite Pharmaceuticals Inc /de/ is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Elite Pharmaceuticals Inc /de/
NameRoleNamed in
Chris DickExecutive officerJun 2009
Mark GittelmanExecutive officerJun 2009
Barry DashDirectorJun 2009
Chris DickDirectorJun 2009
Jerry TreppelDirectorJun 2009
Melvin Van WoertDirectorJun 2009
Robert J. LevensonDirectorJun 2009

Went public since 2012. Its SEC number is that of a company listed on a stock exchange.